BIIB - Biogen Inc Debt to Book Capitalization Ratio

Corporate company logo of Biogen Corp (BIIB)

Biogen Inc. is integrating ESG standards, having achieved climate neutrality and minimized toxic impact on the brain. This attracts top neuroscientists whose developments are supported by generous funding. The total debt-to-book capitalization ratio reflects the dynamics of the capital structure, where the value has stabilized at 0.47. However, the high cost of therapy is triggering protests from insurers, forcing the company to provide discounts.

Biogen Idec (BIIB) - Debts to Book Value from 07/04/2022 to 10/27/2026

Biogen Inc (BIIB) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Quotes Biogen Inc.|BIIB - Analyst Consensus Forecast
- market capitalization data:
Market Value Biogen Idec|BIIB - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Biogen|BIIB - Total Stockholders' Equity|Market Capitalization to Book Value Ratio biogen.com|BIIB - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Capital Biogen Inc.|BIIB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Biogen Corp|BIIB - Company Cumulative Debt|Debts to Book Capitalization Biogen Idec
Fundamental company analysis:Biogen Inc., BIIB
Brand item of Biogen Corp

This indicator reflects the ratio of total credit obligations to net asset value, allowing for an assessment of financial leverage and the risks of capital structure overheating. Analyzing the percentage of debt to book capitalization helps determine the resilience of Biogen Inc. (BIIB) to pressure from insurance companies that limit revenue from innovative drugs through mandatory discounts and strict price caps.

Competitors of Biogen Inc.

Debt to Book Value NBIX (Neurocrine Biosciences)|regencellbioscience.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Axsome Therapeutics, Inc. (AXSM)|ACAD: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio XENE|Viking Therapeutics Corp (VKTX) - Debts to Book Value|Debts to Book Capitalization Supernus Pharmaceuticals|Debt to Book Capitalization Ratio catalystpharma.com|DNLI (Denali Therapeutics Inc.) - Debts to Book Capitalization|Debts to Net Assets HRMY (Harmony Biosciences Inc)|BHVN: Debt to Book Capitalization Ratio|Debts to Book Value Amylyx Corp AMLX|Debts to Book Capitalization TRVI|PRAX - Debt to Net Assets|Debts to Book Capitalization AVXL|CBLL (CeriBell Inc) - Debts to Book Value|Debt to Book Capitalization Ratio Prothena Corporation (PRTA)|Debt to Book Value Ratio Alector Therapeutics (ALEC)|Annexon, Inc. (ANNX) - Debt to Book Value|Debt to Net Assets Ratio omeros.com (OMER)|Debts to Book Capitalization NGNE|AC Immune S.A. - Debts to Net Assets|Voyager Pharma (VYGR) - Debt to Book Capitalization Ratio|NMRA - Debt to Book Value Ratio|SCLX (Scilex Holding Company) - Debts to Book Capitalization|Debt to Book Value tevogen.com|ACOG: Debt to Book Value|Debts to Net Assets Cognition Therapeutics Inc.|Debts to Book Capitalization Inhibikase (IKT)|Debt to Book Capitalization Ratio Cassava Pharma (SAVA)|Debts to Book Capitalization ASRT|Debts to Net Assets Coya Therapeutics Inc COYA|Debts to Book Capitalization VTGN (VistaGen Therapeutics Inc)|OVID - Debts to Net Assets|Acumen Pharma (ABOS) - Debts to Book Capitalization|CRVO (CervoMed Corporation) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio Alterity Therapeutics Ltd. (ATHE)|Debt to Book Value Ratio Clene Nanomedicine|PepGen Inc. - Debts to Book Capitalization|Debts to Book Value Jupiter Neurosciences, Inc. JUNS|Debt to Book Value RLMD (Relmada)|Annovis Bio Corporation - Debts to Book Capitalization|Debt to Book Capitalization Ratio Grace Tx (GRCE)|AIFF: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio KLTO|NeuroSense Therapeutics Ltd. (NRSN) - Debts to Book Value|Debts to Book Capitalization Reviva Pharmaceuticals Holdings|Debt to Book Capitalization Ratio MetaVia, Inc.|NRXS (NeurAxis, Inc.) - Debts to Book Capitalization|Debts to Net Assets HSDT (heliusmedical.com)|PASG: Debt to Book Capitalization Ratio|Debts to Book Value Neuphoria Therapeutics, Inc. NEUP|Debts to Book Capitalization NERV|ATHA - Debt to Net Assets|Debts to Book Capitalization ADXN|ALZN (Alzamend Neuro) - Debts to Book Value|Debt to Book Capitalization Ratio Cyclerion Therapeutics Inc. (CYCN)|Debt to Book Value Ratio Protagenic (PTIX)|Pasithea Therapeutics (KTTA) - Debt to Book Value|Debt to Net Assets Ratio cortigent.com (CRGT)|Debts to Book Capitalization ATXI|brainstorm-cell.com - Debts to Net Assets|Cara Therapeutics (CARA) - Debt to Book Capitalization Ratio|CHRO - Debt to Book Value Ratio|ELYM (eliemtx.com) - Debts to Book Capitalization|Debt to Book Value Intra-Cellular Therapies, Inc.|LBPH: Debt to Book Value|Debts to Net Assets marinuspharma.com|Debts to Book Capitalization NKGen Biotech (NKGN)|Debt to Book Capitalization Ratio NeuroBo Pharmaceuticals Inc (NRBO)|Debts to Book Capitalization SAGE|Debts to Net Assets Synaptogenix, Inc SNPX|Debts to Book Capitalization TRVN (Trevena, Inc.)|VIGL - Debts to Net Assets|Anew Medical (WENA) - Debts to Book Capitalization|CERE (Cerevel Therapeutics Inc) - Debt to Book Capitalization Ratio